Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6654238 | 0.84 | LTA4H (0.41) | SMN1; SMN2LMNAMEN1KMT2A | |
| SCHEMBL27562939 | 0.72 | MAPT (0.32) | MAPTNPSR1KDM4ELMNA | |
| SCHEMBL2362320 | 0.67 | MAPT (0.35) | HPGDNPC1RAB9ASMN1; SMN2CYP3A4 | |
| SCHEMBL2677295 | 0.67 | HPGD (0.38) | HPGDNPC1RAB9ASMN1; SMN2CYP3A4 | |
| SCHEMBL28274802 | 0.67 | AR (0.41) | — | |
| SCHEMBL574986 | 0.65 | NPSR1 (0.38) | HPGDNPC1RAB9ASMN1; SMN2CYP3A4 | |
| SCHEMBL6272216 | 0.65 | SIGMAR1 (0.41) | HPGDNPC1RAB9ASMN1; SMN2CYP3A4 | |
| SCHEMBL105023 | 0.65 | SIGMAR1 (0.41) | HPGDNPC1RAB9ASMN1; SMN2CYP3A4 | |
| SCHEMBL8756913 | 0.65 | HPGD (0.40) | HPGDNPC1RAB9ASMN1; SMN2CYP3A4 | |
| SCHEMBL28053371 | 0.64 | NPC1 (0.36) | HPGDNPC1RAB9ASMN1; SMN2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 129 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3369728-B1 | THERMALLY ACTIVATED DELAYED FLUORESCENCE MATERIAL AND APPLICATION THEREOF IN ORGANIC ELECTROLUMINESCENT DEVICE | KUNSHAN GOVISIONOX OPTOELECTRONICS CO LTD (CN) | 2020-12-23 | — | — | EP | claimed |
| US-20190074447-A1 | THERMALLY ACTIVATED DELAYED FLUORESCENCE MATERIAL AND APPLICATION THEREOF IN ORGANIC ELECTROLUMINESCENCE DEVICE | KUNSHAN GO-VISIONOX OPTO-ELECTRONICS CO., LTD. (CN) | 2019-03-07 | — | — | US | claimed |
| US-20050123906-A1 | Protein modulation | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-06-09 | — | — | US | claimed |
| EP-0504290-B1 | INHIBITORS OF PNEUMOCYSTIS CARINII DIHYDROFOLATE REDUCTASE | CHIRON CORP (US) | 1997-01-22 | — | — | EP | claimed |
| EP-0504290-A4 | INHIBITORS OF PNEUMOCYSTIS CARINII DIHYDROFOLATE REDUCTASE | — | 1993-03-24 | — | — | EP | claimed |
| EP-0504290-A1 | INHIBITORS OF PNEUMOCYSTIS CARINII DIHYDROFOLATE REDUCTASE. | PROTOS CORP (US) | 1992-09-23 | — | — | EP | claimed |
| WO-1991008667-A1 | INHIBITORS OF PNEUMOCYSTIS CARINII DIHYDROFOLATE REDUCTASE | PROTOS CORPORATION (US) | 1991-06-27 | — | — | WO | claimed |
| WO-1991008668-A1 | INHIBITORS OF PNEUMOCYSTIS CARINII DIHYDROFOLATE REDUCTASE | PROTOS CORPORATION (US) | 1991-06-27 | — | — | WO | claimed |
| CN-114276273-B | Organic electroluminescent material based on tetraphenylhydrazine derivative and electronic device thereof | 维思普新材料（苏州）有限公司 | 2024-06-21 | — | — | CN | disclosed |
| CN-114573499-B | 9, 9-Dicarbazole derivative, preparation method thereof and application thereof in luminescence | 维思普新材料（苏州）有限公司 | 2024-05-10 | — | — | CN | disclosed |
| CN-117402130-A | 1,3, 4-triaryl substituted dibenzofuran compound and light-emitting device thereof | 维思普新材料（苏州）有限公司 | 2024-01-16 | — | — | CN | disclosed |
| CN-116655666-A | Boron-containing organic compound and light-emitting device | 中国科学技术大学 | 2023-08-29 | — | — | CN | disclosed |
| CN-116217529-B | Fluorene furan compound and light-emitting device thereof | 维思普新材料（苏州）有限公司 | 2023-07-28 | — | — | CN | disclosed |
| CN-116217529-A | Fluorene furan compound and light-emitting device thereof | 维思普新材料（苏州）有限公司 | 2023-06-06 | — | — | CN | disclosed |
| EP-0504290-A1 | INHIBITORS OF PNEUMOCYSTIS CARINII DIHYDROFOLATE REDUCTASE. | PROTOS CORP (US) | 1992-09-23 | — | — | EP | disclosed |
| WO-1991008667-A1 | INHIBITORS OF PNEUMOCYSTIS CARINII DIHYDROFOLATE REDUCTASE | PROTOS CORPORATION (US) | 1991-06-27 | — | — | WO | disclosed |
| WO-1991008667-A1 | INHIBITORS OF PNEUMOCYSTIS CARINII DIHYDROFOLATE REDUCTASE | PROTOS CORPORATION (US) | 1991-06-27 | — | — | WO | disclosed |
| WO-1991008668-A1 | INHIBITORS OF PNEUMOCYSTIS CARINII DIHYDROFOLATE REDUCTASE | PROTOS CORPORATION (US) | 1991-06-27 | — | — | WO | disclosed |
| WO-1991008668-A1 | INHIBITORS OF PNEUMOCYSTIS CARINII DIHYDROFOLATE REDUCTASE | PROTOS CORPORATION (US) | 1991-06-27 | — | — | WO | disclosed |
| EP-0339555-A2 | Water soluble preparations of coccidiostatics | HOECHST AKTIENGESELLSCHAFT (DE) | 1989-11-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190074447-A1 | THERMALLY ACTIVATED DELAYED FLUORESCENCE MATERIAL AND APPLICATION THEREOF IN ORGANIC ELECTROLUMINESCENCE DEVICE | KCNH1, KCNH2, KCNH3 | HPGD 4501/4885NPC1 3294/4885RAB9A 1332/4885 |
| US-20050123906-A1 | Protein modulation | MAVS, PPP4R3A, PPP1R10 | HPGD 3801/4885NPC1 2184/4885RAB9A 2402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.